Speaker Profile
Ph.D., Director, Bioscience, ImpriMed
Biography
Ilona Holcomb is a molecular biotechnologist with over two decades of experience in academia and cancer research. Specializing in genomic instability in breast and prostate cancers, she has greatly contributed to understanding these complex diseases. Ilona earned her Ph.D. in Molecular Biotechnology from the University of Washington, focusing on prostate cancer. She furthered her research at Stanford University as a Postdoctoral Fellow in Cancer Biology, delving into genomic underpinnings of the aggressive basal-like breast cancer. Known for her innovative and collaborative approach, Ilonas work integrates Next Generation Sequencing (NGS) to address critical questions in cancer biology. Ilonas commitment to cancer research reflects her passion for advancing treatment strategies and diagnostic techniques in the field.
Clinical Dx Showcase:
ImpriMed
ImpriMed provides an anticancer drug efficacy prediction service using artificial intelligence on a patient's live cancer cell data, aiming to help oncologists personalize a treatment regimen tailored to each patient's unique cancer in both human and veterinary oncology.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
